JMP Securities Issues Positive Forecast for HealthEquity (NASDAQ:HQY) Stock Price

HealthEquity (NASDAQ:HQY) had its target price raised by analysts at JMP Securities from $110.00 to $117.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. JMP Securities’ price objective would indicate a potential upside of 2.50% from the stock’s previous close.

HQY has been the topic of a number of other reports. Royal Bank of Canada initiated coverage on HealthEquity in a research report on Thursday, May 22nd. They issued an “outperform” rating and a $112.00 target price on the stock. The Goldman Sachs Group lowered their price target on HealthEquity from $107.00 to $94.00 and set a “neutral” rating for the company in a report on Thursday, March 27th. Raymond James upgraded HealthEquity from an “outperform” rating to a “strong-buy” rating and lowered their price target for the company from $120.00 to $115.00 in a report on Tuesday, March 25th. Wells Fargo & Company boosted their price target on HealthEquity from $110.00 to $125.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $112.00 target price on shares of HealthEquity in a research report on Friday, April 11th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $113.58.

HealthEquity Price Performance

HealthEquity stock traded up $10.39 during midday trading on Wednesday, reaching $114.15. The company’s stock had a trading volume of 410,742 shares, compared to its average volume of 814,026. The firm has a market capitalization of $9.87 billion, a PE ratio of 104.70, a P/E/G ratio of 1.60 and a beta of 0.45. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20. HealthEquity has a fifty-two week low of $65.01 and a fifty-two week high of $115.84. The stock’s 50 day simple moving average is $89.98 and its 200 day simple moving average is $97.56.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings results on Tuesday, June 3rd. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.81 by $0.16. The company had revenue of $330.80 million during the quarter, compared to analysts’ expectations of $322.25 million. HealthEquity had a return on equity of 9.70% and a net margin of 8.41%. During the same quarter in the previous year, the business earned $0.80 EPS. On average, equities research analysts forecast that HealthEquity will post 2.32 earnings per share for the current year.

Insider Activity at HealthEquity

In other news, Director Robert W. Selander sold 5,750 shares of the business’s stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $77.65, for a total transaction of $446,487.50. Following the completion of the sale, the director now owns 84,969 shares of the company’s stock, valued at $6,597,842.85. The trade was a 6.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael Henry Fiore sold 8,881 shares of the company’s stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $78.26, for a total transaction of $695,027.06. Following the sale, the executive vice president now owns 56,655 shares in the company, valued at $4,433,820.30. This represents a 13.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of HealthEquity

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wealthfront Advisers LLC acquired a new stake in shares of HealthEquity in the fourth quarter valued at about $10,304,089,000. Invesco Ltd. increased its stake in HealthEquity by 50.6% during the 1st quarter. Invesco Ltd. now owns 2,446,198 shares of the company’s stock worth $216,171,000 after buying an additional 821,425 shares during the period. T. Rowe Price Investment Management Inc. purchased a new stake in HealthEquity during the 4th quarter worth approximately $78,107,000. Norges Bank purchased a new stake in HealthEquity during the 4th quarter worth approximately $74,701,000. Finally, Nuveen LLC acquired a new position in HealthEquity during the 1st quarter worth approximately $53,076,000. Institutional investors and hedge funds own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.